Navidea Biopharmaceuticals, Inc. – April 28, 2016 Navidea Biopharmaceuticals, Inc. 5600 Blazer Parkway, Suite 200 Dublin, OH 43017-1367 Attention: CFO Tel: 614-973-7474 Fax: 614-793-7522 E-Mail: [email protected] E-Mail in Care Of: [email protected] Kevin W. Waite Moomjian, Waite & Coleman, LLP (May 3rd, 2016)
Stemline Therapeutics Inc. – Separation Agreement (October 29th, 2015)
This Separation Agreement (this Agreement) is made and entered into between ERIC ROWINSKY, M.D. (Executive) and STEMLINE THERAPEUTICS, INC. (the Company).
Shareholders' Agreement (February 26th, 2014)
This Shareholders' Agreement (this "Agreement") is made and entered into effective as of the 20th day of February, 2014 by and among the undersigned shareholders of Coronado Biosciences, Inc., a Delaware corporation (hereinafter referred to as the "Corporation"), who are currently serving as Directors (hereinafter referred to individually as a "Shareholder" and collectively as the "Shareholders").
Navidea Biopharmaceuticals, Inc. – August 20, 2012 Eric Rowinsky MD (August 30th, 2012)
Navidea Biopharmaceuticals, Inc. – August 3, 2011 Eric Rowinsky, MD (August 4th, 2011)
Coronado Biosciences, Inc. Consulting Agreement (July 15th, 2011)
THIS CONSULTING AGREEMENT (the Agreement) is made and entered into as of September 21, 2010 (the Effective Date), by and between CORONADO BIOSCIENCES, INC. (the Company) and ERIC ROWINSKY, M.D. (the Advisor). The Company and the Advisor may be referred to herein individually as a Party or collectively, as Parties.
Agreement (March 22nd, 2010)
This Agreement dated March 20, 2010 (this Agreement), is by and among the persons and entities listed on Schedule A (collectively, the Icahn Group, and individually a member of the Icahn Group) and Biogen Idec Inc. (on behalf of itself and its Board of Directors, as defined herein) (the Company). In consideration of and reliance upon the mutual covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:
Consulting Agreement (March 18th, 2010)
This Consulting Agreement (this Agreement) is entered into effective as of November 23, 2009 by and between ADVENTRX Pharmaceuticals, Inc., a Delaware corporation (the Company), and Eric K. Rowinsky, an individual (Consultant).
ImClone Systems – AMENDED AND RESTATED CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT FOR ERBITUX (R) IN JAPAN (February 29th, 2008)
THIS AMENDED AND RESTATED CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT FOR ERBITUX(r) IN JAPAN (this Agreement), effective as of October 12, 2007 (the Restatement Effective Date), is entered into by and among Bristol-Myers Squibb Company, a corporation organized and existing under the laws of the State of Delaware, having offices located at Route 206 & Province Line Road, Princeton, New Jersey (Bristol), E.R. Squibb & Sons, LLC, a limited liability company organized and existing under the laws of the State of Delaware, having offices located at Route 206 & Province Line Road, Princeton, New Jersey (ERS) (Bristol and ERS, collectively, BMS), Bristol-Myers K. K., a Japanese corporation, with its principal place of business at Shinjuku I-Land Tower, 5-1, Nishi-Shinjuku 6-chome, shinjuku-ku, Tokyo, 163-1328, Japan (BMKK), Merck KGaA, a German corporation with general partners organized and existing under the laws of the Federal Republic of Germany, having offices located at Frankfurte
ImClone Systems – Survival Data Available From Two Randomized Erbitux Studies in Metastatic Colorectal Cancer (November 6th, 2006)
New York, NY--November 6, 2006--ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced results from two randomized Phase III trials of ERBITUX(r) (cetuximab) in patients with metastatic colorectal cancer. These are the first large, randomized studies to examine the impact of ERBITUX treatment on overall survival in colon cancer.